Stockwatch: Stings in the bifurcating tail
This article was originally published in Scrip
Executive Summary
With the major pharmaceutical and biotechnology companies having reported after three weeks into the second quarter 2011 earnings season, in ordinary times most investors would start to relax as the long list of loss-making companies report their financial results in a tail of announcements that can extend almost to the third quarter season in October. These aren’t normal times however, and the fears of a prolonged stagnation of the US economy, sovereign debt default and contagion amongst European member states have been unwelcome diversions of August business as usual in the stock markets.
You may also be interested in...
Stock Watch: Is Johnson & Johnson Edging Away From Pharma?
J&J’s Medtech division outshone pharma while recently launched innovative products contributed minimally: it is to be hoped investors’ reactions to the first set of big pharma Q1 results will not set the tempo for earnings season.
Stock Watch: Risk And The Pharmaceutical Discount Rate
In contrast to the SEC’s view that public companies’ regulatory filings give investors all the information needed to make an investment decision, the discount rate used to value a company may not reflect all its risks.
Stock Watch: Pharma Businesses That Leave Consumer Behind
Healthcare conglomerates that divorce consumer, animal health and even generics businesses from their pure-play branded pharmaceutical groups could leave a less diversified and riskier sector in uncertain times. But the advantages are apparent.